A retrospective study assessing the impact of IL1 inhibitors Anakinra and Canakinumab therapies on patient-reported outcomes in patients with Adult-onset still's disease
Latest Information Update: 21 Jun 2021
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary)
- Indications Adult-onset Still's disease
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism